Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive vs Nonintensive Chemotherapy in Older Patients With AML or MDS
NCT00005823Phase 3Completed
- Sponsor
- Blood Cancer UK
- Start
- Dec 1998
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cytarabine, daunorubicin, valspodar, hydroxyurea and tretinoin in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (10 arms), sponsored by Blood Cancer UK. Primary endpoints: Overall Survival, Response achievement and 1 more. Started Dec 1998; status: completed.
02
Drugs
cytarabinedaunorubicinvalspodarhydroxyureatretinoin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00005823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005823.